Biopharma companies are crabbing up their drug research & development spending after staying stable all the way through last couple of years. According to industry sources, research & development investments will top $ 136 billion in 2013, up from $ 134 billion (2012); also the R&D expenditures estimated to exceed ($ 149 billion) by 2017.
Drug Development Costs: Average cost to develop a drug
* Early 2000s = $ 1.2 billion approx
* Late 1990s = $ 800 million
* Mid 1980s = $ 320 million
* 1970s = $ 140 million
New medicine development – Big investors:
* According to recent industry surveys: NovoNordisk will have the fastest growth in Research & Development spending, from $ 1.8 billion in 2011 to $ 3.1 billion in 2018, an 8 % increase in investments.
* Novartis is predicted to spend on R&D the most $ 10.1 billion – by 2018.
* Roche is expected to spend $ 8.7 billion.
* Merck & Co., is expected to spend $ 7.6 billion.
* GlaxoSmithKline, is expected to spend $ 7.2 billion
* Pfizer, is expected to spend $ 6.7 billion
* Sanofi, is expected to spend $ 6.7 billion
* Johnson & Johnson, is expected to spend $ 5.9 billion
* Eli Lily, is expected to spend $ 4.7 billion
* Bristol-Meyers Squib, is expected to spend $ 4.2 billion
* AstraZeneca is expected to spend $ 4.1 billion: according to the sources several major biopharma companies are expected to spend less on R&D over the next 6 years (including Pfizer, Merck & Co, AstraZeneca and Eli Lilly.)
Medicines in Development:
* Global development in 2011 = 5,400 compounds
* Potential first-in-class medicines (medicines that use a different mechanism of action from any other already approved medicine) in clinical development globally = 70%
Most promising pipeline drugs:
Here are projections for some of the most closely followed drug products either in Phase III trials or which have filed applications for marketing approval.
* GS-7977, (a Hepatitis C polymerase inhibitor) developed by Gilead Life Sciences, believed one of the most worthful drugs in development. Analysts are already anticipating global sales could attain $ 5.4 billion by 2018.
* BG-12, (dimethyl fumarate- for the treatment of relapsing-remitting multiple sclerosis) developed by Biogen Idec, estimate to reach $ 3.4 billion in sales by 2018.
* RG1273 (pertuzumab for the treatment of breast cancer), developed by Roche, estimate to reach $ 2.5 billion.
* Quad, (a combination of elvitegravir, cobicistat, emtricitabine plus tenofovir disoproxil fumarate) for HIV-1, developed by Gilead Sciences, projected, $ 2.8 billion.
* Tofacitinib, (a JAK-3 inhibitor) used for rheumatoid arthritis developed by Pfizer, projected $ 1.7 billion.
* Trastuzumab emtansine (an Anti-HER2 MAb-DM1 conjugate) for breast cancer, developed by Roche, $ 1.1 billion projected.
* Tresiba, (a long-acting insulin), developed by Novo Nordisk, $ 1 billion projected.
* Bexsero,(Meningococcal B vaccine) developed by Novartis, $ 1 billion projected.
* Vascepa, (an Omega-3 fatty acid) for hypertriglyceridemia developed by Amarin Pharmaceuticals. Projected sales could reach $ 510 million.
By WolfBlur from Pixabay